You are here
Consultation: Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Mometasone
This consultation closes on 17 September 2021
The Therapeutic Goods Administration (TGA) is seeking comments from interested parties on proposed advisory statements for labels of over the counter (OTC) medicines containing mometasone in dermal and nasal spray preparations, for inclusion in the Required Advisory Statements for Medicine Labels (RASML). The proposal to include advisory statements for mometasone-containing medicines in RASML follows recent down-scheduling of mometasone for dermal use when supplied under specific conditions, from Schedule 4 to Schedule 3 of the Poisons Standard.
For more information and to participate in the consultation, please visit consultation hub.
The consultation opens on Friday 6 August 2021. Interested parties should respond by close of business Friday 17 September 2021.
Any questions relating to submissions should be emailed to email@example.com.